Dr. Yuri Maricich
Chief Medical Officer & Head of Clinical Development
Dr. Maricich leads the Clinical/Regulatory team at Pear Therapeutics as the Chief Medical Officer and Head of Clinical Development. He collaborates with the executive team on management and strategy. He leads and manages the clinical development programs from Discovery/TPP to Therapeutic Translational Clinical Development through Regulatory submission and prosecution. He leads the team for Pear’s reSET clinical program including the team and strategy for their De Novo Request/Submission of reSET to the FDA which was cleared by the FDA as the first prescription digital therapeutic to treat disease. In addition to overseeing subsequent pipeline programs including reSET-O (1st drug/software combination) Dr. Maricich leads Medical Affairs responsible for successful coverage decisions and works closely with the Pear BD team on business development and biopharma deals and partnerships. Dr. Maricich is a licensed board-certified physician investor clinical developer and strategist. He works to improve patient health and our healthcare system by providing care investing in advising and providing leadership at innovative firms. He has worked with and lead successful teams and programs at Healthcare & Life Science/biotech (HLS) firms including Corixa (acquired by GlaxoSmithKline) Xdynia (acquired by Cavion) Cavion AWS and Pear Therapeutics (1st FDA-cleared clinically validated digital therapeutic to treat disease) and maintains clinical practice. He founded a digital health firm while a 3rd year med student that used AI and NLP to structure clinical data. Dr. Maricich earned his M.D. degree at the University of Washington School of Medicine and his M.B.A from Harvard University.